Interní Med. 2014; 16(2): 50-53

Delaying vascular complications of diabetes

doc.MUDr.Michal Vrablík, Ph.D.
III. interní klinika 1. LF UK a VFN Praha

Vascular complications are among the most common chronic complications of type 2 diabetes mellitus and the major cause of morbidity

and mortality in these patients. The risk of coronary events is increased threefold in male diabetics and even fivefold in female diabetics

in comparison with non-diabetics. In order to reduce a (very) high cardiovascular risk in diabetic patients, a combination of lifestyle measures

and medication therapy is used. Lifestyle measures favourably affect hyperglycaemic control as well as other risk factors associated

with insulin resistance. Pharmacological treatment to prevent macrovascular changes involves renin-angiotensin-aldosterone system

blockade (ACE inhibitor or AT1 blocker), management of dyslipidaemia with a statin, and administration of metformin provided there

are no contraindications. Reducing a persistent residual risk in a diabetic patient is possible with a combination with other strategies

(combination therapy for hypertension, addition of fenofibrate to the treatment of microvascular complications, choice of additional

antihyperglycaemic strategies – pioglitazone, possible incretin-based therapy of diabetes, or properly managed insulin therapy). An

actual delay or prevention of vascular complications of diabetes can be achieved by means of a comprehensive and intensive intervention

made, if possible, as early as prediabetic stages.

gliptins.

Keywords: type 2 diabetes mellitus, microvascular, macrovascular, lifestyle measures, RAS blockade, statins, fibrates, metformin, pioglitazone,

Published: April 20, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M. Delaying vascular complications of diabetes. Interní Med. 2014;16(2):50-53.
Download citation

References

  1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006 Jan 14; 332(7533): 73-78. Go to original source... Go to PubMed...
  2. International Diabetes Federation. Time to Act. 2001. Available at: http://www.idf.org/webdata/docs/Diabetes%20and%20CVD.pdf.
  3. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375: 2215-2222. Go to original source... Go to PubMed...
  4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2005; 366: 1640-1649. Go to original source... Go to PubMed...
  5. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139. Go to original source... Go to PubMed...
  6. Folstrom BC, Jardine AG, Schmieder RG, et al. Rosuvastatin and cardiovascular disease in patients undergoing hemodialysis. N Engl J Med 2009, 360: 1395-1407. Go to original source... Go to PubMed...
  7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct9; 359(15): 1577-1589. Go to original source... Go to PubMed...
  8. Nathan DM, Zinman B, Cleary PA, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/ epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169: 1307-1316. Go to original source... Go to PubMed...
  9. Rydén L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developer in collaboration with the EASD. European Heart Journal, doi: 10.1093/eurheartj/eht108.
  10. Definice metabolického syndromu podle Českého institutu metabolického syndromu, o.p.s. Dostupná z: http://www.cims-ops.cz/cz/uvod. Cit. 24. 1. 2010.
  11. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. Go to original source... Go to PubMed...
  12. The Look Ahead Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154. Go to original source... Go to PubMed...
  13. Gaede P, Lund-Andersen H, Patving H, Pedersen O. Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes, N Eng J Med 2008; 358: 2580-2591. Go to original source... Go to PubMed...
  14. Filipovský J, Widimský J Jr, Ceral R, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Hypertenze KV prevence 2012; 1: 1-16.
  15. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 2011 Jul; 217 (1): 3-46. Go to original source... Go to PubMed...
  16. Vrablík M. Léčba dyslipidemií. Acta Medicinae 2013, 3: 41-48.
  17. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007; 29: 74-83. Go to original source... Go to PubMed...
  18. Takase H, Dohi Y, Okado T, et al. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest. 2012 Dec; 42(12): 1287-1294. Go to original source... Go to PubMed...
  19. Kikuchi K, Nezu U, Inazumi K, et al. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb. 2012; 19(12): 1093-1101. Go to original source... Go to PubMed...
  20. Perk J, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Prev Cardiol. 2012 Aug; 19 (4): 585-667. Go to original source... Go to PubMed...
  21. Scheen AJ. Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract. 2012 Nov; 98(2): 175-86. Go to original source... Go to PubMed...
  22. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013 Oct 3; 369(14): 1317-1326. Go to original source... Go to PubMed...
  23. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3; 369(14): 1327-1335. Go to original source... Go to PubMed...
  24. Haluzík M, Trachta P, Mráz M. Léčba inzulínem a kardiovaskulární komplikace. DMEV 2013, 16: 138-143.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.